These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 29147860)

  • 1. 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
    J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
    Albano D; Bertoli M; Ferro P; Fallanca F; Gianolli L; Picchio M; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):589-597. PubMed ID: 27619357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT in splenic marginal zone lymphoma.
    Albano D; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2018 Oct; 43(10):2721-2727. PubMed ID: 29500652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary mucosa-associated lymphoid tissue lymphoma:
    Albano D; Borghesi A; Bosio G; Bertoli M; Maroldi R; Giubbini R; Bertagna F
    Br J Radiol; 2017 Nov; 90(1079):20170311. PubMed ID: 28830222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
    Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.
    Karunanithi S; Sharma P; Roy SG; Vettiyil B; Sharma A; Thulkar S; Bal C; Kumar R
    Clin Nucl Med; 2014 Sep; 39(9):772-6. PubMed ID: 25036015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
    Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
    Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
    Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.
    Albano D; Bosio G; Treglia G; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):77-84. PubMed ID: 28822997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between
    Zhao J; Wang H
    J Med Imaging Radiat Oncol; 2021 Apr; 65(2):188-194. PubMed ID: 33538120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation.
    Albano D; Bosio G; Giubbini R; Bertagna F
    Leuk Lymphoma; 2017 Oct; 58(10):2328-2334. PubMed ID: 28270020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers.
    Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Simonitsch-Klupp I; Raderer M; Mayerhoefer ME
    Acad Radiol; 2018 Apr; 25(4):453-460. PubMed ID: 29199055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation?
    Purandare NC; Puranik A; Shah S; Agrawal A; Gupta T; Moiyadi A; Shetty P; Shridhar E; Jalali R; Rangarajan V
    Nucl Med Commun; 2017 Dec; 38(12):1109-1116. PubMed ID: 28922334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Dual-Phase FDG PET/CT in the Diagnosis and Follow-Up of Brain Tumors.
    Özütemiz C; Neil EC; Tanwar M; Rubin NT; Ozturk K; Cayci Z
    AJR Am J Roentgenol; 2020 Oct; 215(4):985-996. PubMed ID: 32841063
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
    Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT and primary hepatic MALT: a case series.
    Albano D; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2016 Oct; 41(10):1956-9. PubMed ID: 27259334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT findings in endometrial cancer patients: the correlation between SUVmax and clinicopathologic features.
    Boonya-ussadorn T; Choi WH; Hyun J; Kim SH; Chung SK; Yoo IeR
    J Med Assoc Thai; 2014 Feb; 97 Suppl 2():S115-22. PubMed ID: 25518184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma.
    Ponisio MR; McConathy J; Laforest R; Khanna G
    Pediatr Radiol; 2016 Aug; 46(9):1258-68. PubMed ID: 27003132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.